(2018). The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: Results from a 6-month, open-label Phase I clinical trial.
Chicago Style (17th ed.) CitationThe Anti-CD6 Antibody Itolizumab Provides Clinical Benefit Without Lymphopenia in Rheumatoid Arthritis Patients: Results from a 6-month, Open-label Phase I Clinical Trial. 2018.
MLA (8th ed.) CitationThe Anti-CD6 Antibody Itolizumab Provides Clinical Benefit Without Lymphopenia in Rheumatoid Arthritis Patients: Results from a 6-month, Open-label Phase I Clinical Trial. 2018.
Warning: These citations may not always be 100% accurate.